HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)

Market Cap	6.60B +6.5%
Revenue (ttm)	2.12B -11.5%
Net Income	411.58M +71.0%
EPS	0.18 +74.4%
Shares Out	2.23B
PE Ratio	16.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,481,232
Open	2.560
Previous Close	2.940
Day's Range	2.560 - 2.990
52-Week Range	2.370 - 4.080
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHE:002437

HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People’s Republic of China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 2,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002437

Financial Performance

In 2025, SHE:002437's revenue was 2.14 billion, a decrease of -12.51% compared to the previous year's 2.44 billion. Earnings were 376.91 million, an increase of 61.93%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error